• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Pharvaris N.V.

    8/14/25 5:56:17 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PHVS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    Pharvaris N.V.

    (Name of Issuer)


    Ordinary shares, par value EURO0.12 per share

    (Title of Class of Securities)


    N69605108

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    N69605108


    1Names of Reporting Persons

    Venrock Healthcare Capital Partners III, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,047,620.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,047,620.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,047,620.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.8 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    N69605108


    1Names of Reporting Persons

    VHCP Co-Investment Holdings III, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,047,620.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,047,620.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,047,620.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.8 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    N69605108


    1Names of Reporting Persons

    Venrock Healthcare Capital Partners EG, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,047,620.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,047,620.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,047,620.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.8 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    N69605108


    1Names of Reporting Persons

    VHCP Management III, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,047,620.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,047,620.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,047,620.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.8 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    N69605108


    1Names of Reporting Persons

    VHCP Management EG, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,047,620.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,047,620.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,047,620.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.8 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    N69605108


    1Names of Reporting Persons

    Nimish Shah
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,047,620.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,047,620.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,047,620.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    N69605108


    1Names of Reporting Persons

    Bong Y. Koh
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,047,620.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,047,620.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,047,620.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Pharvaris N.V.
    (b)Address of issuer's principal executive offices:

    Emmy Noetherweg 2, Leiden, P7, 2333.
    Item 2. 
    (a)Name of person filing:

    The names of the persons filing this report (collectively, the "Reporting Persons") are: Venrock Healthcare Capital Partners III, L.P. ("VHCP III") VHCP Co-Investment Holdings III, LLC ("VHCP Co-Investment III") Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG") VHCP Management III, LLC ("VHCP Management III") VHCP Management EG, LLC ("VHCP Management EG") Nimish Shah ("Shah") Bong Koh ("Koh") The Reporting Persons are members of a group for the purposes of this Schedule 13G.
    (b)Address or principal business office or, if none, residence:

    New York Office: 7 Bryant Park, 23rd Floor New York, NY 10018 Palo Alto Office: 3340 Hillview Avenue Palo Alto, CA 94304
    (c)Citizenship:

    All of the entities were organized in Delaware. Shah and Koh are both United States citizens.
    (d)Title of class of securities:

    Ordinary shares, par value EURO0.12 per share
    (e)CUSIP No.:

    N69605108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference. The Reporting Persons' ownership of the Issuer's securities consists of (i) 380,109 ordinary shares held by VHCP III, (ii) 38,028 ordinary shares held by VHCP Co-Investment III, and (iii) 1,629,483 ordinary shares held by VHCP EG. VHCP Management III is the general partner of VHCP III and the manager of VHCP Co-Investment III. VHCP Management EG is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCP Management III and VHCP Management EG.
    (b)Percent of class:

    Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the shares of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference. The percentage set forth in Row 11 of each Reporting Person's cover page is based upon 54,493,142 ordinary shares of the Issuer outstanding as of March 31, 2025, as reported in the Issuer's prospectus supplement dated July 22, 2025, filed with the Securities and Exchange Commission (the "SEC") on July 24, 2025.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.

     (ii) Shared power to vote or to direct the vote:

    Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.

     (iii) Sole power to dispose or to direct the disposition of:

    Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.

     (iv) Shared power to dispose or to direct the disposition of:

    Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of June 30, 2025 and is incorporated by reference.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Venrock Healthcare Capital Partners III, L.P.
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By VHCP Management III, LLC, its General Partner, By Sherman G. Souther, Authorized Signatory
    Date:08/14/2025
     
    VHCP Co-Investment Holdings III, LLC
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By VHCP Management III, LLC, its Manager, By Sherman G. Souther, Authorized Signatory
    Date:08/14/2025
     
    Venrock Healthcare Capital Partners EG, L.P.
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By VHCP Management EG, LLC, its General Partner, By Sherman G. Souther, Authorized Signatory
    Date:08/14/2025
     
    VHCP Management III, LLC
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By Sherman G. Souther, Authorized Signatory
    Date:08/14/2025
     
    VHCP Management EG, LLC
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By Sherman G. Souther, Authorized Signatory
    Date:08/14/2025
     
    Nimish Shah
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By Sherman G. Souther, Attorney-in-fact
    Date:08/14/2025
     
    Bong Y. Koh
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By Sherman G. Souther, Attorney-in-fact
    Date:08/14/2025
    Exhibit Information

    Exhibit 24.1 Power of Attorney for Nimish Shah (incorporated by reference to Exhibit B to Schedule 13G filed on November 30, 2023) Exhibit 24.2 Power of Attorney for Bong Koh (incorporated by reference to Exhibit C to Schedule 13G filed on November 30, 2023) Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit A to Schedule 13G filed on November 30, 2023)

    Get the next $PHVS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PHVS

    DatePrice TargetRatingAnalyst
    6/11/2025$32.00Buy
    Guggenheim
    4/29/2025$28.00Overweight
    Cantor Fitzgerald
    9/25/2023$27.00Outperform
    Wedbush
    8/15/2023$10.00 → $34.00Equal-Weight → Overweight
    Morgan Stanley
    10/5/2022$16.00Buy
    Bryan Garnier
    9/13/2022$34.00 → $18.00Mkt Outperform
    JMP Securities
    8/23/2022$40.00 → $10.00Overweight → Equal-Weight
    Morgan Stanley
    8/22/2022$26.00 → $13.00Neutral → Underperform
    BofA Securities
    More analyst ratings

    $PHVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update

    Topline results for RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, expected in 4Q2025Enrollment continues in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline results expected in 2H2026Startup activities for CREAATE, a pivotal Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks, on track; study is expected to initiate by YE2025Strong financial position with cash and cash equivalents of €200 million as of June 30, 2025; subsequent closing of $201 million public offering extends cash runway into 1H2027 ZUG, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Phar

    8/12/25 4:05:00 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

    ZUG, Switzerland, July 24, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (("Pharvaris, NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the closing of its previously announced upsized underwritten public offering of 9,562,500 ordinary shares (which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,312,500 ordinary shares) and pre-funded warrants to purchase 500,000 ordinary shares. The gross proc

    7/24/25 4:05:58 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

    ZUG, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (("Pharvaris, NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced today the pricing of an underwritten offering of (i) 8,250,000 of its ordinary shares at a price of $20.00 per share and (ii) to one investor, pre-funded warrants to purchase 500,000 ordinary shares at a price of $19.99 per pre-funded warrant, which represents the per share public offering price for the ordinary shar

    7/22/25 9:22:41 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Pharvaris N.V. with a new price target

    Guggenheim initiated coverage of Pharvaris N.V. with a rating of Buy and set a new price target of $32.00

    6/11/25 7:54:51 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Pharvaris N.V. with a new price target

    Cantor Fitzgerald initiated coverage of Pharvaris N.V. with a rating of Overweight and set a new price target of $28.00

    4/29/25 8:11:22 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wedbush initiated coverage on Pharvaris N.V. with a new price target

    Wedbush initiated coverage of Pharvaris N.V. with a rating of Outperform and set a new price target of $27.00

    9/25/23 7:40:10 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHVS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Pharvaris N.V.

    SCHEDULE 13G/A - Pharvaris N.V. (0001830487) (Subject)

    8/14/25 5:56:17 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Pharvaris N.V.

    6-K - Pharvaris N.V. (0001830487) (Filer)

    8/12/25 4:10:22 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Pharvaris N.V.

    6-K - Pharvaris N.V. (0001830487) (Filer)

    7/24/25 4:18:38 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHVS
    Financials

    Live finance-specific insights

    View All

    Pharvaris Provides Business Update and Expands Development Program for Deucrictibant

    CHAPTER-3, the global pivotal Phase 3 clinical study of deucrictibant for the prophylactic treatment for HAE using once-daily extended-release tablet, is expected to initiate by YE2024Differentiated deucrictibant profile, including long-term extension results, to be highlighted in clinical, real-world, nonclinical, and discovery data presentations at the 2024 Bradykinin SymposiumPharvaris intends to pursue clinical development in acquired angioedema as a newly named indicationPharvaris to host a conference call today at 8:00 a.m. ET ZUG, Switzerland, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 rece

    9/5/24 6:50:00 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks

    Primary endpoint met; 40 mg/day orally administered deucrictibant significantly reduced mean monthly attack rate by 84.5% (p=0.0008) compared to placebo92.3% reduction in occurrence of moderate and severe attacks92.6% fewer attacks treated with on-demand medication by participantsDeucrictibant well-toleratedPharvaris to host a conference call today at 8:00 a.m. EST ZUG, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced positive top-line data from the CHAPTER-1 Phase 2 clinical study meeting its primary endpoi

    12/6/23 6:50:00 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks

    Primary endpoint met, substantially reducing HAE attack symptomsAll secondary endpoints metPHVS416 was well tolerated at all dose levelsPharvaris to host a conference call today at 8:00 a.m. ET ZUG, Switzerland, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced positive top-line data from the RAPIDe-1 Phase 2 clinical study, demonstrating statistically significant results of PHVS416 as an oral on-demand treatment for HAE attacks. Pharvaris plans to present data from the study at future medical meetings. RAPIDe-1 Clinical Stu

    12/8/22 6:50:00 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Pharvaris N.V. (Amendment)

    SC 13G/A - Pharvaris N.V. (0001830487) (Subject)

    2/14/24 8:42:52 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Pharvaris N.V. (Amendment)

    SC 13G/A - Pharvaris N.V. (0001830487) (Subject)

    2/14/24 10:27:18 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Pharvaris N.V. (Amendment)

    SC 13G/A - Pharvaris N.V. (0001830487) (Subject)

    2/13/24 2:14:59 PM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PHVS
    Leadership Updates

    Live Leadership Updates

    View All

    NodThera Announces Appointment of Elisabeth Björk as Board Member

    NodThera Announces Appointment of Elisabeth Björk as Board Member Former SVP at AstraZeneca R&D brings deep expertise in obesity and cardiometabolic research, portfolio strategy development and commercializationAppointment follows commencement of Phase 2 RESOLVE-1 trial of oral NLRP3 inflammasome inhibitor NT-0796 in patients with obesity Philadelphia, PA, June 17, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appointment of Elisabeth Björk, M.D., Ph.D. as Board Member. Elisabeth has more than 20 years of experience in late-stage cl

    6/17/25 7:00:00 AM ET
    $PHVS
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vicore Expands and Strengthens its Board of Directors

    STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

    5/14/24 2:20:00 AM ET
    $KRON
    $MACK
    $MXCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch
    Biotechnology: Laboratory Analytical Instruments

    Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer

    ZUG, Switzerland, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the appointment of Stefan Abele, Ph.D., as Chief Technical Operations Officer. In this role, he will be responsible for all chemistry, manufacturing, and controls (CMC) activities, supply chain, and program management as Pharvaris progresses into late-stage clinical development. Dr. Abele joins Pharvaris with more than 20 years of experience in process development, end-to-end Active Pharmaceutical Ingredients (API) supply chain, cross-functional CMC activities

    11/15/23 6:50:00 AM ET
    $PHVS
    Biotechnology: Pharmaceutical Preparations
    Health Care